Mgc Pharmaceuticals Ltd

MXC

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

Argent Biopharma Limited

RGT

Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.

BetaShares Crypto Innovators ETF

CRYP

CRYP.AX was created on 2021-11-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. CRYP.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to global companies at the forefront of the crypto economy.

Global Battery Tech & Lithium Companies

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

Vanguard Australian Shares High Yield ETF

VHY

VHY.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax.